https://www.nasdaq.com/press-release/aileron-therapeutics-provides-business-update-and-outlines-2022-strategic-priorities
https://www.nasdaq.com/press-release/aileron-therapeutics-to-present-at-upcoming-investor-conferences-2022-01-04
https://www.nasdaq.com/press-release/aileron-therapeutics-issues-statement-on-passing-of-scientific-advisory-board-member
https://www.nasdaq.com/press-release/aileron-therapeutics-reports-third-quarter-2021-financial-results-and-business
https://www.nasdaq.com/press-release/aileron-therapeutics-presents-data-at-aacr-nci-eortc-international-conference
https://www.nasdaq.com/press-release/aileron-therapeutics-announces-presentation-of-new-preclinical-data-at-upcoming-aacr
https://www.nasdaq.com/press-release/aileron-therapeutics-presents-new-clinical-data-at-esmo-virtual-congress-2021
https://www.nasdaq.com/press-release/aileron-therapeutics-to-present-new-clinical-data-at-esmo-virtual-congress-2021
https://www.nasdaq.com/press-release/aileron-therapeutics-to-present-at-upcoming-h.c.-wainwright-virtual-global-0
https://www.nasdaq.com/press-release/aileron-therapeutics-presents-initial-findings-from-ongoing-healthy-volunteer-study
https://www.nasdaq.com/press-release/aileron-therapeutics-reports-second-quarter-2021-financial-results-and-provides
https://www.nasdaq.com/press-release/aileron-therapeutics-to-participate-in-fireside-chat-at-the-william-blair-biotech
https://www.nasdaq.com/press-release/aileron-therapeutics-announces-initiation-of-randomized-double-blind-placebo
https://www.nasdaq.com/press-release/aileron-therapeutics-to-be-added-to-the-russell-microcapr-index-2021-06-24
https://www.nasdaq.com/press-release/aileron-therapeutics-to-host-kol-virtual-investor-event-discussing-opportunity-for
https://www.nasdaq.com/press-release/aileron-therapeutics-reports-first-quarter-2021-financial-results-and-provides
https://www.nasdaq.com/press-release/aileron-therapeutics-reports-fourth-quarter-and-full-year-2020-financial-results-and
https://www.nasdaq.com/press-release/aileron-therapeutics-to-present-at-2021-h.c.-wainwright-global-life-sciences
https://www.nasdaq.com/press-release/aileron-therapeutics-announces-enrollment-expansion-for-upcoming-phase-1b-clinical
https://www.nasdaq.com/press-release/aileron-therapeutics-announces-completion-of-%2435.9-million-registered-direct-offering
https://www.nasdaq.com/press-release/aileron-therapeutics-announces-%2435.9-million-registered-direct-offering-2021-01-06
https://www.nasdaq.com/press-release/aileron-therapeutics-provides-business-update-and-outlines-2021-strategic-priorities
https://www.nasdaq.com/press-release/aileron-therapeutics-reports-third-quarter-2020-financial-results-and-business
https://www.nasdaq.com/press-release/aileron-therapeutics-announces-proof-of-concept-clinical-data-from-ongoing-alrn-6924
https://www.nasdaq.com/press-release/aileron-therapeutics-to-host-conference-call-to-discuss-results-from-phase-1b-proof
https://www.nasdaq.com/press-release/aileron-therapeutics-announces-proof-of-concept-data-for-alrn-6924-to-be-featured-in
https://www.nasdaq.com/press-release/aileron-therapeutics-announces-common-stock-purchase-agreement-for-up-to-%2415-million
https://www.nasdaq.com/press-release/aileron-therapeutics-to-present-at-upcoming-h.c.-wainwright-virtual-global-investment
https://www.nasdaq.com/press-release/aileron-therapeutics-reports-second-quarter-2020-financial-results-and-provides
https://www.nasdaq.com/press-release/aileron-therapeutics-to-present-at-two-upcoming-investor-conferences-in-august-2020
https://www.nasdaq.com/press-release/aileron-therapeutics-announces-completion-of-enrollment-in-dose-optimization
https://www.nasdaq.com/press-release/aileron-therapeutics-initiates-enrollment-in-schedule-optimization-part-of-phase-1b-2
https://www.nasdaq.com/press-release/aileron-therapeutics-announces-closing-of-public-offering-of-common-stock-and
https://www.nasdaq.com/press-release/aileron-therapeutics-announces-pricing-of-public-offering-of-common-stock-2020-06-04
https://www.nasdaq.com/press-release/aileron-therapeutics-announces-proposed-public-offering-of-common-stock-2020-06-03
https://www.nasdaq.com/press-release/aileron-therapeutics-announces-positive-interim-results-from-phase-1b-2-clinical
https://www.nasdaq.com/press-release/aileron-therapeutics-announces-initiation-of-expansion-cohort-and-first-patient
https://www.nasdaq.com/press-release/aileron-therapeutics-reports-first-quarter-2020-financial-results-and-provides
https://www.nasdaq.com/press-release/aileron-therapeutics-announces-plans-to-release-interim-results-from-its-phase-1b-2
https://www.nasdaq.com/press-release/aileron-therapeutics-reports-fourth-quarter-and-full-year-2019-financial-results-2020
https://www.nasdaq.com/press-release/aileron-therapeutics-announces-the-promotion-of-richard-j.-wanstall-to-chief
https://www.nasdaq.com/press-release/aileron-therapeutics-reports-third-quarter-2019-results-2019-11-07
https://www.nasdaq.com/press-release/aileron-therapeutics-to-report-third-quarter-2019-financial-results-on-november-7th
https://www.nasdaq.com/press-release/aileron-therapeutics-announces-positive-nonclinical-myelopreservation-results-for
https://www.nasdaq.com/press-release/aileron-to-present-nonclinical-myelopreservation-data-for-alrn-6924-at-the-2019-aacr
https://www.nasdaq.com/press-release/aileron-therapeutics-announces-the-initiation-of-patient-treatment-in-its-first
https://www.nasdaq.com/press-release/aileron-presents-positive-interim-phase-2a-data-for-alrn-6924-in-combination-with
https://www.nasdaq.com/press-release/aileron-to-present-interim-phase-2a-clinical-data-for-alrn-6924-in-combination-with
